Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

Indeed, additional promising drugs with multitarget activity (including ... Alternative RTK pathways that are activated following EGFR inhibition is another area for investigation.

Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient ...

There are many assets with many different mechanism of actions going into the EGFR development pipeline, which is quite exciting. The most advanced, I will say, have to be antibody drug conjugates.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

In October 2024, Lutris successfully completed enrollment in the international phase 2 trial of LUT014 in patients with metastatic colorectal cancer (mCRC) treated with EGFRi therapy who develop ...

PACC mutation is around the 12% of all EGFR. So there are newer drug development specifically aiming for those space, including exon 20. We have amivantamab approved in combination with chemo in ...

The U.S. Food and Drug Administration (FDA ... with Vectibix (panitumumab), an epidermal growth factor receptor (EGFR) inhibitor, as a late-line option for metastatic colorectal cancer (mCRC).

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment. The leading c-MET-NSCLC Companies such as ...